

## Special Issue

# State-of-the-Art Research on Multiple Myeloma Progression

### Message from the Guest Editor

Multiple myeloma is a type of blood cancer that occurs when malignant plasma cells accumulate in the bone marrow. In recent years, science has made significant progress in understanding the molecular pathways involved in myeloma development and developing new drugs to treat the disease. One crucial area of research has been the identification of genetic mutations and alterations that contribute to the development of myeloma. Another area of focus has been the development of immunotherapies, which harness the immune system's power to fight cancer. Bench-to-bedside development is a vital process that enables the development of new therapies for myeloma, leading to improved patient outcomes and survival. The current state-of-the-art therapies in myeloma include immunomodulatory drugs, proteasome inhibitors, monoclonal antibodies, T-cell engagers, CAR-T cell therapies, and XPO-1 inhibitors. The recent advances in myeloma research and drug development offer hope for improved outcomes for patients with this challenging disease.

---

### Guest Editor

Dr. Shebli Atrash

Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health Wake Forest University School of Medicine, Charlotte, NC 28204, USA

---

### Deadline for manuscript submissions

closed (30 November 2024)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/171881](https://mdpi.com/si/171881)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)